PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

06 дек 2024 08:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

03 дек 2024 08:00:33 Источник Nasdaq GlobeNewswire

PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results

14 ноя 2024 08:00:01 Источник Nasdaq GlobeNewswire

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

06 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

22 окт 2024 08:00:01 Источник Nasdaq GlobeNewswire

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

02 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

16 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

09 сен 2024 08:00:47 Источник Nasdaq GlobeNewswire

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results

13 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting

08 авг 2024 08:00:01 Источник Nasdaq GlobeNewswire

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

07 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024

05 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

01 авг 2024 07:45:00 Источник Nasdaq GlobeNewswire

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

31 июл 2024 16:01:00 Источник Nasdaq GlobeNewswire

PDS Biotech to Participate at BTIG Virtual Biotechnology Conference

29 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer

12 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

15 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

09 май 2024 17:46:46 Источник Nasdaq GlobeNewswire

PDS Biotech to Participate in Upcoming May 2024 Investor Conferences

09 май 2024 08:00:00 Источник Nasdaq GlobeNewswire